Rucaparib is licensed as a single-agent in the US  Patients using Olaparib, benefited for a long period of time

Rucaparib is licensed as a single-agent in the US Patients using Olaparib, benefited for a long period of time

Cancer-News

2 years
161 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how Rucaparib is licensed as a single-agent in the US Patients using Olaparib, benefited for a long period of time.
Up Next Autoplay